Get the Stockscreener App
30.26
5.11%
1.47
After Hours:
30.34
0.08
+0.26%
Indivior Pharmaceuticals Inc stock is traded at $30.26, with a volume of 2.20M.
It is up +5.11% in the last 24 hours and down -10.02% over the past month.
Indivior Pharmaceuticals Inc is a specialty pharmaceutical company singularly focused on delivering evidence-based treatment and advancing understanding of opioid use disorder (OUD) as a chronic but treatable brain disease. The company derives revenues from customers through the development, manufacture and sale of buprenorphine-based prescription drugs for treatment of opioid dependence and related disorders. The company's products include: Sublocade (buprenorphine extended-release monthly injection), and Suboxone (buprenorphine and naloxone sublingual film).
See More
Previous Close:
$28.79
Open:
$29.03
24h Volume:
2.20M
Relative Volume:
0.81
Market Cap:
$3.78B
Revenue:
$1.24B
Net Income/Loss:
$209.00M
P/E Ratio:
18.22
EPS:
1.6605
Net Cash Flow:
$-94.86M
1W Performance:
-0.88%
1M Performance:
-10.02%
6M Performance:
+32.66%
1Y Performance:
+215.87%
1-Day Range:
$29.03
$30.64
1-Week Range:
$27.68
$30.99
52-Week Range:
$8.64
$38.00
Indivior Pharmaceuticals Inc Stock (INDV) Company Profile
Name
Indivior Pharmaceuticals Inc
Sector
Phone
804-379-1090
Address
10710 MIDLOTHIAN TURNPIKE, NORTH CHESTERFIELD
Compare INDV vs TAK, ZTS, HLN, TEVA, UTHR
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
INDV
Indivior Pharmaceuticals Inc
|
30.26 | 3.60B | 1.24B | 209.00M | -94.86M | 1.6605 |
TAK
Takeda Pharmaceutical Co Adr
|
18.29 | 56.99B | 29.85B | 776.90M | 4.35B | 0.2408 |
ZTS
Zoetis Inc
|
116.71 | 48.94B | 9.47B | 2.67B | 2.28B | 6.0218 |
HLN
Haleon Plc Adr
|
9.74 | 43.30B | 14.54B | 2.22B | 2.58B | 0.4871 |
TEVA
Teva Pharmaceutical Industries Ltd Adr
|
29.46 | 33.94B | 17.41B | 1.43B | 1.00B | 1.2182 |
UTHR
United Therapeutics Corp
|
541.60 | 23.31B | 3.18B | 1.33B | 1.04B | 27.90 |
Indivior Pharmaceuticals Inc Stock (INDV) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Aug-06-25 | Initiated | H.C. Wainwright | Buy |
| Jul-22-25 | Resumed | Jefferies | Buy |
| Jan-28-25 | Initiated | Rodman & Renshaw | Buy |
| Jul-23-24 | Initiated | Piper Sandler | Overweight |
| Apr-03-24 | Initiated | Craig Hallum | Buy |
| Jul-13-23 | Initiated | Northland Capital | Outperform |
View All
Indivior Pharmaceuticals Inc Stock (INDV) Latest News
Indivior PLC Stock Faces Uncertainty Amid U.S. Domicile Shift and OUD Market Focus - AD HOC NEWS
If You Invested $1,000 in Indivior Pharmaceuticals Inc. (INDV) - Stock Titan
Indivior Pharmaceuticals Inc (INDV) Shares Up 5.07% on Mar 25 - GuruFocus
Indivior, Liquidia, Crinetics top Quant pharma list as Merck scoops up Terns for $6.7B (XLV:NYSEARCA) - Seeking Alpha
Down 12.9% Over the Past Month: Reasons to Consider Purchasing Indivior Pharmaceuticals Inc. (INDV) During the Decline - Bitget
Down 12.9% in 4 Weeks, Here's Why You Should You Buy the Dip in Indivior Pharmaceuticals Inc. (INDV) - Yahoo Finance
FDA Grants Priority Tag to Ionis' NDA for Alexander Disease Drug - TradingView
[SCHEDULE 13G] Indivior... - Stock Titan
Indivior Pharmaceuticals to report Q4 earnings: What's in the cards? - MSN
A Look At Indivior Pharmaceuticals (NasdaqGS:INDV) Valuation After Recent Share Price Weakness - Sahm
Implied volatility surging for Indivior Pharmaceuticals stock options - MSN
Indivior Pharmaceuticals Inc (INDV) Shares Gap Down to $29.44 on Mar 20 - GuruFocus
Indivior (NASDAQ:INDV) Upgraded by Zacks Research to "Strong-Buy" Rating - MarketBeat
Goldentree Asset Management LP Makes New Investment in Indivior PLC $INDV - MarketBeat
Indivior outlines 30% adjusted EBITDA growth target for 2026 with new $400M share repurchase program - MSN
Indivior Issues $500 Million Convertible Senior Notes Offering - TipRanks
[Form 4] Indivior Pharmaceuticals, Inc. Insider Trading Activity - Stock Titan
Indivior Pharmaceuticals Raises $500 Million Via 0.625% Convertible Notes Due 2031 - TradingView
Indivior Pharmaceuticals Survey Reveals Gaps in Medications for Opioid Use Disorder in U.S. Jails and Prisons - Quiver Quantitative
National Survey Finds Only 58% of U.S. Correctional Facilities Offer Medications for Opioid Use Disorder - GlobeNewswire
Indivior plans $400M convertible senior notes offering - MSN
Indivior PLC $INDV Shares Acquired by Divisadero Street Capital Management LP - MarketBeat
Indivior plans $400 million convertible notes offering By Investing.com - Investing.com Nigeria
Does Indivior’s Upsized Convertible Notes and Buybacks Shift the Bull Case For Indivior (INDV)? - simplywall.st
How Indivior’s Upsized $450 Million Convertible Notes and Buybacks May Impact Indivior (INDV) Investors - Yahoo Finance
Melqart Asset Management UK Ltd Increases Position in Indivior PLC $INDV - MarketBeat
Indivior PLC $INDV is Mangrove Partners IM LLC's Largest Position - MarketBeat
Indivior director Kingsley buys $29,953 in shares By Investing.com - Investing.com Nigeria
Is It Too Late To Consider Indivior Pharmaceuticals (INDV) After A 221% One Year Surge? - simplywall.st
Indivior prices $450 million convertible notes offering By Investing.com - Investing.com Australia
Insider Buying: Barbara Ryan Acquires Shares of Indivior Pharmac - GuruFocus
INDV SEC FilingsIndivior Pharmaceuticals Inc. 10-K, 10-Q, 8-K Forms - Stock Titan
Indivior Pharmaceuticals prices upsized $450M convertible senior notes - MSN
Indivior PLC Stock (ISIN: US45580R1068) Drops 6% as $450M Convertible Notes Offering Signals Capital - AD HOC NEWS
Indivior (NASDAQ:INDV) Sees Strong Trading VolumeTime to Buy? - MarketBeat
Analysts Are Bullish on These Healthcare Stocks: Indivior (INDV), Gyre Therapeutics (GYRE) - The Globe and Mail
Indivior Prices Upsized Convertible Notes for Debt Refinancing - TipRanks
Indivior prices upsized $450M 0.625% convertible notes due 2031 - TradingView
Indivior (INDV) Upsizes Convertible Notes Offering to $450M - GuruFocus
Indivior Prices Upsized $450 Million Senior Notes Offering - marketscreener.com
Indivior Announces Proposed Convertible Senior Notes Offering - Sahm
Indivior Prices $450 Million Convertible Senior Notes Offering - National Today
Indivior (INDV) Plans $400 Million Convertible Notes Offering - GuruFocus
Indivior Prices Upsized $450.0 Million Convertible Senior Notes Offering - GlobeNewswire
Indivior plans $400 million convertible notes offering - Investing.com South Africa
Indivior prices $450 million convertible notes offering - Investing.com
Indivior Pharmaceuticals Announces Pricing of $450 Million Convertible Senior Notes Offering - Quiver Quantitative
Indivior (NASDAQ:INDV) Shares Gap DownWhat's Next? - MarketBeat
Indivior proposes $400M convertible senior notes due 2031 to refinance debt, fund buybacks - TradingView
Indivior Pharmaceuticals Inc Stock (INDV) Financials Data
Revenue
Net Income
Cash Flow
EPS
3.12%
1.13%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):